KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 129 filers reported holding KEROS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,691,840 | +41.8% | 53,069 | +78.7% | 0.00% | – |
| Q2 2023 | $1,192,944 | +19.3% | 29,690 | +26.8% | 0.00% | – |
| Q1 2023 | $1,000,000 | +50100.8% | 23,420 | -43.5% | 0.00% | – |
| Q4 2022 | $1,992 | -99.7% | 41,481 | +133.4% | 0.00% | – |
| Q3 2022 | $669,000 | +59.3% | 17,771 | +16.7% | 0.00% | – |
| Q2 2022 | $420,000 | -79.4% | 15,224 | -59.4% | 0.00% | – |
| Q1 2022 | $2,041,000 | +5.1% | 37,528 | +13.0% | 0.00% | – |
| Q4 2021 | $1,942,000 | +368.0% | 33,199 | +216.1% | 0.00% | – |
| Q3 2021 | $415,000 | +5.6% | 10,502 | +13.3% | 0.00% | – |
| Q2 2021 | $393,000 | 0.0% | 9,271 | +45.1% | 0.00% | – |
| Q1 2021 | $393,000 | -4.4% | 6,389 | +9.5% | 0.00% | – |
| Q4 2020 | $411,000 | +302.9% | 5,834 | +124.6% | 0.00% | – |
| Q3 2020 | $102,000 | +15.9% | 2,597 | +10.8% | 0.00% | – |
| Q2 2020 | $88,000 | – | 2,343 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |